Contraceptive Technology Update – June 1, 2022
June 1, 2022
View Issues
-
Federal Title X Funding Decimated for Many Providers
A shockwave rocked Title X programs on March 30, when the federal government’s latest round of funding left many facilities with huge budget shortfalls. The Biden administration had reversed the gag rule and asked Congress for more Title X funds. Yet, when Title X funding was announced, many programs received the worst cut in their history with the program. -
More Low-Income Women Used IUDs After Introduction of Low- or No-Cost Options
LARC offers many safety and efficacy benefits. But there remain barriers in cost and the need for in-person clinic visits. The results of recent research show that as the cost is decreased, the percentage of women using IUDs increased. -
Research Shows Benefits of Policies Increasing Access to Postpartum LARC
Medicaid expansion and other policies can make postpartum LARC more affordable. States also can create ways to make LARC affordable through programs in which hospitals can bill separately for intrauterine devices and their insertion. -
Now Is the Time to Change Label on Emergency Contraceptives
The FDA should change the labeling for levonorgestrel-based emergency contraception to reflect evidence-based knowledge that the drug does not act as an abortifacient, according to researchers. The label change is especially important now, as states are banning abortions and sometimes defining it in ways that would prohibit pharmacies from selling emergency contraception under its current FDA labeling. -
Intervention Focuses on Contraceptives and Reproductive Life Plan for Teens
Teen mothers need tangible support to help them with their contraceptive decisions and to prevent unintended rapid-repeat births, according to recent research. The AIM 4 Teen Moms program is a future-oriented behavioral intervention that can help influence teen mothers’ attitudes, intentions, and contraceptive use and behaviors. -
Study Shows Low-Sensitivity Pregnancy Tests Work Well After Medication Abortion
Contraceptive Technology Update asked Patricia A. Lohr, MD, MPH, medical director and director of the Centre for Reproductive Research & Communication at the British Pregnancy Advisory Service in the United Kingdom to explain how her new study’s findings suggest the usefulness of the low-sensitivity urine pregnancy test for use after a self-managed medication abortion. -
Title X Funding Cuts Could Worsen STI Rates
In March, the federal government sent Title X health providers a budget that will result in further slashes to programs that screen, test, trace, and treat people with STIs. STI rates are rising sharply for the sixth year in a row. -
CDC Updates Trichomoniasis Treatment Guidelines
Although trichomoniasis likely is the most common nonviral STI in the world, and is potentially dangerous for birth outcomes, it is largely overlooked in screening and diagnosis. The CDC recently updated its STI treatment guidelines, recommending women with trichomoniasis receive multidose metronidazole 500 mg twice daily for seven days. -
Research Suggests Need for Improved Abdominal Pain Screening
When adolescent females present at EDs with abdominal pain, they are inconsistently diagnosed through a gynecological history and pelvic exam. Sometimes, this can lead to the wrong treatment, which suggests a need for comprehensive sexual and gynecological health intake, according to researchers.